Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create ...

Today, a brief rundown of news involving Eisai, Biogen and Sanofi, as well as updates from Opthea, Novartis, and PTC Therapeutics. Expected readouts in diabetes, cancer and depression headline a ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Reduction-in-force notices went out Tuesday morning to employees across HHS. At FDA, OND director Peter Stein is departing as ...

Artis is launching at a critical time for genetic medicine research. Funding for developers of the therapies dropped in 2024 as investors looked for less risky bets. Meanwhile, Trump administration ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

In his resignation letter, Marks cited disagreement with HHS Secretary Robert F. Kennedy Jr., who he said pushed ...

The sweeping workforce reduction that began Tuesday was made worse by mistakes and poor communication, including directions ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

The FDA will lose about 3,500 employees under the plans, although HHS said drug, medical device and food reviewers will not ...